Ballentine Partners LLC Takes $38,000 Position in CureVac (NASDAQ:CVAC)

Ballentine Partners LLC bought a new stake in CureVac (NASDAQ:CVAC) during the first quarter, according to its most recent disclosure with the SEC. The firm bought 12,597 shares of the company’s stock, valued at approximately $38,000.

Several other hedge funds and other institutional investors have also recently bought and sold shares of CVAC. Vontobel Holding Ltd. acquired a new stake in shares of CureVac during the fourth quarter worth $45,000. Vanguard Personalized Indexing Management LLC acquired a new position in CureVac in the fourth quarter valued at $68,000. International Assets Investment Management LLC acquired a new stake in CureVac during the fourth quarter worth about $71,000. Aristides Capital LLC purchased a new position in shares of CureVac in the 4th quarter worth about $100,000. Finally, China Universal Asset Management Co. Ltd. grew its holdings in shares of CureVac by 351.2% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 25,887 shares of the company’s stock worth $109,000 after purchasing an additional 20,149 shares during the period. 17.26% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts have issued reports on CVAC shares. Leerink Partnrs downgraded shares of CureVac from an “outperform” rating to a “market perform” rating in a research report on Thursday, April 25th. Guggenheim restated a “neutral” rating on shares of CureVac in a research report on Friday, April 5th. Finally, SVB Leerink cut shares of CureVac from an “outperform” rating to a “market perform” rating and cut their target price for the stock from $12.00 to $4.00 in a report on Thursday, April 25th.

CureVac Trading Down 0.1 %

Shares of NASDAQ:CVAC opened at $3.36 on Friday. CureVac has a fifty-two week low of $2.21 and a fifty-two week high of $11.49. The company has a quick ratio of 2.09, a current ratio of 2.25 and a debt-to-equity ratio of 0.08. The company has a market cap of $752.24 million, a PE ratio of -2.53 and a beta of 2.68. The company’s 50-day moving average price is $3.39 and its 200 day moving average price is $3.53.

CureVac (NASDAQ:CVAC) last announced its quarterly earnings data on Thursday, May 23rd. The company reported ($0.34) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.12). CureVac had a negative return on equity of 49.22% and a negative net margin of 463.49%. The business had revenue of $13.43 million during the quarter, compared to analyst estimates of $14.51 million. Sell-side analysts anticipate that CureVac will post -1.11 earnings per share for the current year.

About CureVac

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.